Experienced in Streptococcal Group A Infection

Parham Sendi

Bern, BE, CH 
Experienced in Streptococcal Group A Infection
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Parham Sendi practices in Bern, Switzerland. Mr. Sendi is rated as an Experienced expert by MediFind in the treatment of Streptococcal Group A Infection. His top areas of expertise are Streptococcal Group B Infection, Strep Throat, Septic Arthritis, Intrauterine Device Insertion, and Hip Replacement.

His clinical research consists of co-authoring 165 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Streptococcal Group A Infection.

Gender
Male

Locations

Bern, BE 3010, Switzerland
Other Locations
Basel, BS, Switzerland
Switzerland
Liestal, BL 4410, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Is This PJI Really Acute: A Quantitative Sonication Fluid Analysis
Is This PJI Really Acute: A Quantitative Sonication Fluid Analysis
Enrollment Status: Completed
Publish Date: January 22, 2025
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Enrollment Status: Terminated
Publish Date: November 09, 2021
Intervention Type: Drug
Study Drug: Conestat alfa
Study Phase: Phase 2
View 1 Less Clinical Trial

165 Total Publications

Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study.
Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study.
Journal: Antibiotics (Basel, Switzerland)
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sendi's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile